Skip to content

Ischemia Detection During Development of Acute Compartment Syndrome

Early Ischemia Detection by a Tissue CO2-sensor During Development of Acute Compartment Syndrome

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06079255
Acronym
IDEA
Enrollment
60
Registered
2023-10-12
Start date
2025-10-15
Completion date
2027-10-30
Last updated
2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biosensing Techniques, Blood Circulation Disorder, Carbon Dioxide, Compartment Syndrome of Leg, Ischemia Limb

Keywords

Ischemia, Biosensor, Carbon dioxide, Orthopedic surgery, Limb, Acute compartment syndrome

Brief summary

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome.

Detailed description

This is an open, observational, prospective, descriptive, single-centre study including 60 patients. The study is designed to investigate if IscAlert sensor system can be used for reliable and continuous tissue carbon dioxide (pCO2)- and temperature monitoring in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome. The study will provide information regarding the clinical usefulness of tissue perfusion assessment by pCO2 and temperature monitoring in the diagnosis of patients at risk of developing acute compartment syndrome. Additionally, it will provide information regarding limits of pCO2 and temperature in the tissue indicating the need for fasciotomy. A fasciotomy will be performed independent of the measured pCO2 and temperature measurements in the muscle if clinical signs indicate a development of possible acute compartment syndrome. Measures of pain, and number of infections and bleeding caused by (or assumed to be caused by IscAlert) at insertion site will be registered. The duration of investigation: In a patient: From insertion of first IscAlert™ sensor(s) to discharge from hospital. The sensors will usually be implanted for two days each. Follow up until 30 days after discharge from the hospital. 13 months of inclusion of all patients. There will be one last follow-up visit 1 year after discharge which will only look at sequelae after acute compartment syndrome and not sensors related issues. Primary Aim: To assess if pCO2-levels when assessed with IscAlert correctly indicate the presence of acute compartment syndrome in muscular tissue in lower extremity in patients at risk of developing acute compartment syndrome. Hypotheses 1. The pCO2 measurements will be at least 3 kPa higher when assessed with IscAlert in the muscle compartment where acute compartment syndrome develops compared to compartments where acute compartment syndrome does not develop. 2. No clinically significant pain, bleeding or infection will occur due to using IscAlert. 3. The temperature measurements will be lower when assessed with IscAlert in the muscle compartment where acute compartment syndrome develops compared to compartments where acute compartment syndrome does not develop.

Interventions

DEVICEIscAlert sensor(s) in patient with risk of acute compartment syndrome

of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)

Sponsors

Sensocure AS
CollaboratorINDUSTRY
Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 110 Years

Inclusion criteria

* Must have a leg fracture that, perceived by the clinician, could give rise to later developing acute compartment syndrome condition. * Subject must be 18 years or more. * Able to sign informed consent. * Expected cooperation of the patients for the treatment and follow up

Exclusion criteria

* Another study interfering with current study * Any reason why, in the opinion of the investigator, the patient should not participate. * Patients where a fasciotomy has already been decided should be performed

Design outcomes

Primary

MeasureTime frameDescription
Tissue CO2-level10 daysTissue CO2-level (kPa) during insertion period

Secondary

MeasureTime frameDescription
Infection30 daysInfection from insertion site at the discretion of the investigator (yes or no)
Pain at sensor insertion site30 daysPain at the insertion site measured by Numeric Rating Scale (0= no pain, 10= maximum pain)
Pain in the lower leg during hospitalisation10 daysPain in the injured lower leg measured by Numeric Rating Scale (0= no pain, 10= maximum pain)
Color of the lower leg10 daysSkin color of the injured lower leg (Blue/Pink/Pale/Normal) during hospitalisation
Paresthesia of the lower leg10 daysParesthesia of the injured lower leg (Yes/No) during hospitalisation
Paralysis of the lower leg10 daysParalysis of the injured lower leg (Yes/No) during hospitalisation
Lenght of sensor implantation time10 daysLenght of sensor implantation time during hospitalisation
Time to discovery of reduced blood flow in lower leg10 daysNumber of days and hours from primary surgery end to obstructed blood flow is diagnosed.
Number of re-operations30 daysNumber of reoperations (fasciotomies) caused by acute compartment syndrome
Number of skin grafts performed1 yearNumber of skin grafts performed caused by sequelae after acute compartment syndrome
Number of limb amputations performed1 yearNumber of limb amputations performed caused by sequelae after acute compartment syndrome
Number of sensory deficit conditions1 yearNumber of sensory deficit conditions caused by sequelae after acute compartment syndrome
Number of paralysis conditions1 yearNumber of paralysis conditions caused by sequelae after acute compartment syndrome
Number of rhabdomyolysis conditions1 yearNumber of rhabdomyolysis conditions caused by sequelae after acute compartment syndrome
Number of limb muscle contractures1 yearNumber of limb muscle contractures caused by sequelae after acute compartment syndrome
Bleeding10 daysAmount of blood from insertion site (ml)
Number of acute compartment syndrome conditions after 1 year1 yearNumber of acute compartment syndrome conditions after 1 year
Incidence of death 1 year1 yearMortality 1 year after admission
Incidence of death during hospitalisation30 daysMortality during primary hospitalisation
Lenght of stay during primary hospitalisation30 daysLenght of stay during primary hospitalisation
Number of pack-years30 daysSmoking habit; number of pack-years by participants
Intravenous fluid12 hoursIntravenous fluid given during surgery (ml)
Vasoactive drugs12 hoursVasoactive drugs given during surgery (microgram)
Tissue temperature level10 daysTissue temperature level (grade Celcius) during insertion period
IscAlert functionality10 daysNumber of hours with a well-functioning sensor (giving CO2- and temperature data)
Intracompartmental pressure10 daysIntracompartmental pressure (mmHg) measured in anterior compartment of the injured leg
Systolic blood pressure during hospitalisation10 daysSystolic blood pressure (mmHg) during hospitalisation
Diastolic blood pressure during hospitalisation10 daysDiastolic blood pressure (mmHg) during hospitalisation
Peripheral pulse during hospitalisation10 daysPeripheral distal pulse (rate/minute) at the injured leg during hospitalisation
Hemoglobin10 daysHemoglobin (g/dL) level during hospitalisation
Creatine kinase10 daysCreatine kinase (U/L) level during hospitalisation
Number of acute compartment syndrome conditions during hospitalisation30 daysNumber of acute compartment syndrome conditions during hospitalisation

Countries

Norway

Contacts

Primary ContactJohn Clarke-Jenssen, MD, PhD.
uxclaj@ous-hf.no23027447
Backup ContactTor Inge Tønnessen, MD, Ph.D.
t.i.tonnessen@medisin.uio.no91700717

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026